Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab.

Ortiz-Morales, M José; Toledano-Fonseca, Marta; Mena-Osuna, Rafael; Cano, M Teresa; Gómez-España, Auxiliadora; Haba-Rodríguez, Juan R De la; Rodríguez-Ariza, Antonio; Aranda, Enrique

Ortiz-Morales, M José; Toledano-Fonseca, Marta; Mena-Osuna, Rafael; Cano, M Teresa; Gómez-España, Auxiliadora; Haba-Rodríguez, Juan R De la; Rodríguez-Ariza, Antonio; Aranda, Enrique.

Afiliação

Ortiz-Morales MJ; Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.
Toledano-Fonseca M; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.
Mena-Osuna R; Department of Medicine, Faculty of Medicine, University of Córdoba, 14004 Córdoba, Spain.
Cano MT; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.
Gómez-España A; Cancer Network Biomedical Research Centre (CIBERONC), 28029 Madrid, Spain.
Haba-Rodríguez JR; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.
Rodríguez-Ariza A; Cancer Network Biomedical Research Centre (CIBERONC), 28029 Madrid, Spain.
Aranda E; Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.

Cancers (Basel) ; 14(13)2022 Jun 21.

Article em En | MEDLINE | ID: mdl-35804826

Palavras-chave

VEGF-A; angiotensin-converting enzyme; anti-angiogenic drug; bevacizumab; biomarker; colorectal cancer; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google